Cellenkos gains FDA clearance for CK0802 trial in GVHD
May 05, 2026 | 10:10
Cellenkos has received FDA clearance for its Investigational New Drug application, enabling a Phase 1b/2a trial of CK0802 for steroid-refractory Graft-versus-Host Disease.
Mobile Version